Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) PT at $101.08

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has earned a consensus recommendation of “Moderate Buy” from the fifteen ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, twelve have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $101.3077.

Several analysts have weighed in on the stock. Truist Financial boosted their target price on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Weiss Ratings lowered shares of Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, February 17th. Barclays increased their price objective on shares of Protagonist Therapeutics from $108.00 to $113.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Citigroup raised their target price on shares of Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Finally, TD Cowen upped their target price on Protagonist Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, February 26th.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, CFO Asif Ali sold 46,203 shares of the firm’s stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $83.13, for a total value of $3,840,855.39. Following the sale, the chief financial officer directly owned 60,320 shares in the company, valued at approximately $5,014,401.60. This trade represents a 43.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Arturo Md Molina sold 13,151 shares of the business’s stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $82.42, for a total transaction of $1,083,905.42. Following the transaction, the insider directly owned 84,115 shares of the company’s stock, valued at approximately $6,932,758.30. This trade represents a 13.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 203,167 shares of company stock worth $16,889,199. 4.90% of the stock is owned by company insiders.

Institutional Trading of Protagonist Therapeutics

A number of large investors have recently modified their holdings of the company. Farther Finance Advisors LLC boosted its stake in Protagonist Therapeutics by 110.6% during the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after purchasing an additional 156 shares during the period. Greenline Wealth Management LLC acquired a new stake in shares of Protagonist Therapeutics in the fourth quarter valued at approximately $27,000. Salomon & Ludwin LLC bought a new stake in shares of Protagonist Therapeutics during the third quarter valued at approximately $29,000. EverSource Wealth Advisors LLC raised its holdings in shares of Protagonist Therapeutics by 138.9% during the third quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock valued at $36,000 after buying an additional 314 shares during the last quarter. Finally, Abich Financial Wealth Management LLC acquired a new position in shares of Protagonist Therapeutics during the third quarter worth approximately $62,000. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Stock Down 0.1%

Shares of NASDAQ PTGX opened at $97.09 on Monday. The stock’s 50 day moving average price is $86.37 and its two-hundred day moving average price is $80.45. Protagonist Therapeutics has a 52-week low of $39.60 and a 52-week high of $99.50. The stock has a market capitalization of $6.20 billion, a P/E ratio of -47.36 and a beta of 2.23.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Wednesday, February 25th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.16). Protagonist Therapeutics had a negative return on equity of 19.89% and a negative net margin of 282.83%.The firm had revenue of $7.44 million during the quarter, compared to analyst estimates of $14.92 million. On average, analysts anticipate that Protagonist Therapeutics will post 2.43 EPS for the current year.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.